Search results
Results from the WOW.Com Content Network
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...
20665 Ensembl ENSG00000100146 ENSMUSG00000033006 UniProt P56693 Q04888 RefSeq (mRNA) NM_006941 NM_011437 RefSeq (protein) NP_008872 NP_035567 Location (UCSC) Chr 22: 37.97 – 37.99 Mb Chr 15: 79.04 – 79.05 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Transcription factor SOX-10 is a protein that in humans is encoded by the SOX10 gene. Function This gene encodes a member of the ...
For example, tumor markers like Ki-67 can be used to choose form of treatment or in prognostics but are not useful to give a diagnosis, while other tumor markers have the opposite functionality. Therefore it's important to follow the guidelines of the specific tumor marker. Tumor markers are mainly used in clinical medicine to support a ...
ICD-10 is the 10th revision of the International Classification of Diseases (ICD), a medical classification list by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. [1]
The CEA blood test is not reliable for diagnosing cancer or as a screening test for early detection of cancer. [8] Most types of cancer do not result in a high CEA level. [9] Serum from individuals with colorectal carcinoma often has higher levels of CEA than healthy individuals (above approximately 2.5ng/mL). [10]
In developing prostate cancer, XIAP is one of four IAPs overexpressed in the prostatic epithelium, indicating that a molecule that inhibits all IAPs may be necessary for effective treatment. [15] Apoptotic regulation is an extremely important biological function, as evidenced by "the conservation of the IAPs from humans to Drosophila ".
A panel of epigenetic methylation marker has been explored for prognosis of ovarian cancer, and it is reported that the panel exhibited high specificity and sensitivity (both above 70%) as a screen marker. [5] Epigenetic markers have also shown promising potential as prognostic markers for bladder cancer. [6]
The objective of this study was to compare different tumor markers and their diagnostic value. The tumor markers tested in this experiment were CA 19-9, CA 242 and CEA tumor markers. The data revealed that although each marker have its own level of specificity and correspond to a cancer, all three makers together increase diagnostic value. [7]